Skip to main content
    A

    Arcus Biosciences Inc (RCUS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $22.84
    +0.31 (+1.38%)

    Market Cap: $2.83B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(22/34)
    Avg Surprise
    +26.95%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.86
    Range$-1.00 - $-0.69
    7 analysts
    EPS Revisions
    4
    0
    7d
    4
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.83-4.7%
    60d ago$-0.83-4.7%
    30d ago$-0.88+1.9%
    7d ago$-0.89+2.5%
    Current$-0.86
    Revenue Consensus
    $12M
    Range$6M - $25M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.97
    Range$-1.84 - $-0.28
    7 analysts
    Revenue Consensus
    $15M
    Range$-5840450 - $44M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.97---
    Sep 26EST
    		-$-0.86---
    Jun 26
    Reported Aug 5
    		$-0.72$-0.98+26.53%Beat-
    Mar 26
    Reported May 5
    		$-1.02$-0.83-22.89%Miss+10.5%
    Dec 25
    Reported Feb 25
    		$-0.89$-1.10+19.09%Beat+13.6%
    Sep 25
    Reported Oct 28
    		$-1.27$-1.29+1.55%Beat-27.0%
    Jun 25
    Reported Aug 6
    		$0.00N/A+100.00%Beat+100.0%
    Mar 25
    Reported May 6
    		$-1.14$-1.01-12.87%Miss-700.0%
    Dec 24
    Reported Feb 25
    		$-1.03$-1.20+14.39%Beat+4.6%
    Sep 24
    Reported Nov 6
    		$-1.00$-1.07+6.54%Beat-6.4%
    Jun 24
    Reported Aug 8
    		$-1.02$-1.39+26.62%Beat+1.9%
    Mar 24
    Reported May 8
    		$0.19N/A+118.45%Beat+117.4%
    Dec 23
    Reported Feb 21
    		$-1.08$-1.00-8.00%Miss-16.1%
    Sep 23
    Reported Nov 7
    		$-0.94$-1.10+14.55%Beat-4.4%
    Jun 23
    Reported Aug 7
    		$-1.04$-1.08+3.70%Beat-11.8%
    Mar 23
    Reported May 9
    		$-1.09$-1.17+6.84%Beat-13.5%
    Dec 22
    Reported Feb 28
    		$-0.93$-1.07+13.08%Beat-125.1%
    Sep 22
    Reported Nov 2
    		$-0.90$-1.01+10.89%Beat+18.9%
    Jun 22
    Reported Aug 3
    		$-0.93$-0.95+2.11%Beat+14.7%
    Mar 22
    Reported May 9
    		$-0.96$-0.84-14.29%Miss+11.1%
    Dec 21
    Reported Feb 23
    		$3.71$-0.74+601.35%Beat+552.4%
    Sep 21
    Reported Nov 8
    		$-1.11$-1.03-7.77%Miss-3800.0%
    Jun 21
    Reported Aug 5
    		$-1.09$-0.84-29.76%Miss-17.2%
    Mar 21
    Reported May 5
    		$-1.08$-0.83-30.12%Miss-71.4%
    Dec 20
    Reported Feb 24
    		$-0.82$-0.75-9.33%Miss-115.8%
    Sep 20
    Reported Nov 5
    		$0.03N/A+103.95%Beat+105.9%
    Jun 20
    Reported Aug 6
    		$-0.93$-0.58-60.34%Miss-45.3%
    Mar 20
    Reported May 5
    		$-0.63$-0.56-12.50%Miss-53.7%
    Dec 19
    Reported Mar 5
    		$-0.38$-0.51+25.49%Beat-35.7%
    Sep 19
    Reported Nov 5
    		$-0.51$-0.52+1.92%Beat-104.0%
    Jun 19
    Reported Aug 6
    		$-0.64$-0.41-56.10%Miss-100.0%
    Mar 19
    Reported May 2
    		$-0.41$-0.35-17.14%Miss-10.8%
    Dec 18
    Reported Mar 5
    		$-0.28$-0.45+37.78%Beat+26.3%
    Sep 18
    Reported Nov 8
    		$-0.25$-0.35+28.57%Beat-47.1%
    Jun 18
    Reported Aug 6
    		$-0.32$-0.40+20.00%Beat-
    Mar 18
    Reported May 9
    		$-0.37$-0.43+13.95%Beat-
    Dec 17
    Reported Mar 16
    		$-0.38$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.86EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-234.10%
    ROE-90.80%ROIC-62.78%
    Financial Health
    Debt/Equity0.22xInterest Coverage-40.82x
    Current Ratio3.82xQuick Ratio3.82x
    Trading Statistics
    Beta0.94Avg Volume1.49M
    52-Week High$31.7352-Week Low$16.04

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$23.84
    SMA 20$24.73
    SMA 50$27.07
    SMA 200$24.82
    EMA 10$23.74
    EMA 20$24.60
    EMA 50$26.03
    EMA 200$24.34

    MACD

    Line: -1.09Signal: -0.97Hist: -0.12

    ADX

    ADX: 22.4+DI: 12.9-DI: 30.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$25.54

    Bollinger Bands

    Upper Band$27.09
    Lower Band$22.38
    %B Position1905%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    34.5

    Momentum Oscillators

    Stoch %K5.8
    Stoch %D12.9
    Williams %R-88.0
    ROC (10d)-9.5%
    Momentum-2.39
    CCI (20d)-147.2
    MFI (14d)49.5

    Volatility Measures

    ATR (14d)$1.19(5.2%)
    StdDev (20d)1.18
    Hist Vol44.0%(High)

    Volume Flow

    VWAP$22.86
    OBV50.2M
    AD Line20.6M
    CMF (20d)-0.087

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.8x
    VWMA (20d)$24.80

    Pivot Points

    R3$24.32
    R2$23.90
    R1$23.21
    Pivot Point$22.79
    S1$22.10
    S2$21.68
    S3$20.99

    Advanced Oscillators

    TSI-26.82
    Ultimate Osc39.9
    KST-122.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$41.00M$17.00M$33.00M$26.00M$160.00M$28.00M$26.00M$48.00M$39.00M$145.00M$31.00M$32.00M
    Cost of Revenue$0$0$3.00M$0$0$0$3.00M$0$0$0$5.00M$0
    Gross Profit$41.00M$17.00M$33.00M$26.00M$160.00M$28.00M$26.00M$48.00M$39.00M$145.00M$31.00M$32.00M
    Operating Expenses$137.00M$151.00M$147.00M$168.00M$168.00M$150.00M$129.00M$153.00M$145.00M$161.00M$122.00M$112.00M
    R&D$113.00M$122.00M$121.00M$141.00M$139.00M$122.00M$101.00M$123.00M$115.00M$109.00M$93.00M$82.00M
    SG&A$24.00M$29.00M$26.00M$27.00M$29.00M$28.00M$28.00M$30.00M$30.00M$32.00M$29.00M$30.00M
    Operating Income$-96,000,000$-134,000,000$-114,000,000$-142,000,000$-8,000,000$-122,000,000$-103,000,000$-105,000,000$-106,000,000$-16,000,000$-91,000,000$-80,000,000
    Interest Income$0$0$0$0$0$0$0$0$0$13.00M$0$0
    Interest Expense$3.00M$3.00M$2.00M$3.00M$2.00M$1.00M$2.00M$1.00M$0$1.00M$0$1.00M
    Income Before Tax$-91,000,000$-128,000,000$-106,000,000$-135,000,000$0$-112,000,000$-93,000,000$-92,000,000$-93,000,000$-4,000,000$-80,000,000$-69,000,000
    Income Tax Expense$0$0$0$0$0$0$1.00M$0$0$0$1.00M$2.00M
    Net Income$-91,000,000$-128,000,000$-106,000,000$-135,000,000$0$-112,000,000$-94,000,000$-92,000,000$-93,000,000$-4,000,000$-81,000,000$-71,000,000
    EBITDA$-87,000,000$-126,000,000$-104,000,000$-133,000,000$1.00M$-112,000,000$-106,000,000$-95,000,000$-98,000,000$-19,000,000$-89,000,000$-66,000,000
    EBIT$-88,000,000$-125,000,000$-104,000,000$-132,000,000$2.00M$-111,000,000$-103,000,000$-91,000,000$-93,000,000$-16,000,000$-80,000,000$-68,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RCUS

    News

    JPMorgan starts coverage of Arcus Biosciences stock at Overweight

    JPMorgan initiated coverage of Arcus Biosciences (RCUS) with an Overweight rating and a $41.00 price target. The investment case is centered on casdatifan, an investigational HIF-2a inhibitor for renal cell carcinoma...

    ad-hoc-news.de•10/15/26•Bullish

    JPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target

    JPMorgan has initiated coverage on Arcus Biosciences (NYSE:RCUS) with an Overweight rating and a price target of $41. This new coverage indicates a positive outlook from JPMorgan on the biotechnology company's future...

    Moomoo•10/15/26•Bullish

    Arcus Biosciences, Inc. (RCUS) Stock Forecasts

    Arcus Biosciences Inc. (RCUS) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. Argus has lowered its target price for RCUS to $27.00...

    Yahoo! Finance Canada•10/14/26•Somewhat-Bearish

    JPMorgan initiates Arcus Biosciences stock at Overweight, $41 target

    JPMorgan has initiated coverage on Arcus Biosciences Inc. (NYSE:RCUS) with an Overweight rating and a $41 price target, citing strong prospects for its HIF-2α inhibitor, casdatifan...

    Investing.com•10/14/26•Bullish

    Arcus Biosciences Initiated at Overweight by JP Morgan

    JP Morgan has initiated coverage on Arcus Biosciences (NYSE:RCUS) with an Overweight rating. This indicates a positive outlook from the investment bank regarding the company's stock performance.

    Moomoo•10/14/26•Bullish

    RCUS Valuation and Fair Value

    P/E
    -5.9x
    P/B
    6.2x
    See GNG's fair value

    RCUS Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -234.1%
    Net margin
    0.0%
    ROIC
    -62.8%
    ROE
    -90.8%
    FCF margin
    -406.0%

    RCUS Competitors

    CompanyTicker
    Denali Therapeutics IncDNLI
    Soleno Therapeutics IncSLNO
    Enliven Therapeutics Inc.ELVN
    Dyne Therapeutics IncDYN
    Celcuity LLCCELC
    Privia Health Group IncPRVA
    Warby Parker IncWRBY
    Aveanna Healthcare Holdings IncAVAH

    Sector: Healthcare

    RCUS Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    0
    Buy
    11
    Hold
    2
    Sell
    0
    Strong Sell
    0

    RCUS Bull Case vs Bear Case

    Bull case

    • RCUS beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 84.6% of RCUS's analyst ratings are Buy or Strong Buy.

    Bear case

    • RCUS's quarterly revenue changed -74.4% year over year.

    RCUS Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    16.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.86
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 2 down

    Frequently Asked Questions About RCUS

    Does RCUS pay dividends?

    Arcus Biosciences Inc (RCUS) does not currently pay a regular dividend.

    What is RCUS's market cap?

    Arcus Biosciences Inc (RCUS) has a market capitalization of $2.83B with a current stock price of $22.84.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In